David C. Hodgson
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
TriNet Expands Embedded HR Solutions and AI for SMBs. TriNet announced it is adding embedded HR solutions and new AI features aimed at small and medium‑sized businesses. The move broadens the company’s product lineup and could help it capture more of the growing HR‑tech market. The update comes as the stock trades near its 52‑week high and around key support levels.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ALHC Faces Downgrade and Lower Target Amid Mixed CMS Ratings. Alignment Healthcare shares are trading lower after William Blair downgraded the stock to Market Perform and JP Morgan cut its price target to $10. These moves followed mixed California Star Ratings and news of network expansion, which analysts say highlight ongoing operational challenges. The stock is currently trading near its 52-week low, reflecting the negative sentiment from these recent analyst actions.
Transaction History
| RPRX | ▲ Buy | Grant | 4,545 | $0 | 6/5/2026 | View on chart |
| TNET | ▲ Buy | Grant | 7,378 | $0 | 5/28/2026 | View on chart |
| ALHC | ▲ Buy | Grant | 18,982 | $0 | 3/13/2026 | View on chart |
| TNET | ▲ Buy | Grant | 4,127 | $0 | 5/23/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 7,614 | $0 | 5/13/2025 | View on chart |
| ALHC | ▲ Buy | Grant | 18,710 | $0 | 3/13/2025 | View on chart |
| TNET | ▲ Buy | Grant | 186 | $0 | 10/4/2024 | View on chart |
| RPRX | ▲ Buy | Grant | 9,293 | $0 | 6/7/2024 | View on chart |
| TNET | ▲ Buy | Grant | 2,930 | $0 | 5/24/2024 | View on chart |
| ALHC | ▲ Buy | Grant | 50,000 | $0 | 3/13/2024 | View on chart |
| RPRX | ▲ Buy | Grant | 7,747 | $0 | 6/23/2023 | View on chart |
| TNET | ▼ Sell | Gift | 79,891 | $0 | 5/3/2023 | View on chart |
| TNET | ▲ Buy | Grant | 4,112 | $0 | 3/23/2023 | View on chart |
| ALHC | ▲ Buy | Grant | 36,337 | $0 | 3/8/2023 | View on chart |
| RPRX | ▲ Buy | Grant | 2,346 | $0 | 7/8/2022 | View on chart |
| RPRX | ▲ Buy | Grant | 6,328 | $0 | 6/24/2022 | View on chart |
| TNET | ▲ Buy | Grant | 3,148 | $0 | 3/24/2022 | View on chart |
| ALHC | ▲ Buy | Grant | 16,556 | $0 | 3/8/2022 | View on chart |
| ALHC | ▲ Buy | Grant | 32,823 | $0 | 8/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.